GVAX is one of the first tested vaccines against pancreatic cancer, and it is composed of the irradiated tumor cell-expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) (Le et al., 2015; Yarchoan et al., 2020). The gene discussed is CSF2; the disease is pancreatic neoplasm.